Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer
Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …
negative breast cancer is defined by the presence of the estrogen receptor and/or the …
The CDK4/6 inhibitor revolution—a game-changing era for breast cancer treatment
Abstract Cyclin-dependent kinase (CDK) 4/6 inhibition in combination with endocrine
therapy is the standard-of-care treatment for patients with advanced-stage hormone receptor …
therapy is the standard-of-care treatment for patients with advanced-stage hormone receptor …
Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline
PURPOSE To develop guideline recommendations concerning optimal neoadjuvant therapy
for breast cancer. METHODS ASCO convened an Expert Panel to conduct a systematic …
for breast cancer. METHODS ASCO convened an Expert Panel to conduct a systematic …
Systemic therapy for early-stage breast cancer: learning from the past to build the future
The treatment of breast cancer has improved dramatically over the past century, from a
strictly surgical approach to a coordinated one, including local and systemic therapies …
strictly surgical approach to a coordinated one, including local and systemic therapies …
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future
The development and approval of cyclin-dependent kinase (CDK) 4 and 6 inhibitors for
hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative …
hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative …
Systemic therapy for estrogen receptor–positive, HER2-negative breast cancer
HJ Burstein - New England Journal of Medicine, 2020 - Mass Medical Soc
Estrogen Receptor–Positive Breast Cancer ER-positive, HER2-negative breast cancer,
which accounts for about 70% of all breast cancers, is heterogeneous. Antiestrogen therapy …
which accounts for about 70% of all breast cancers, is heterogeneous. Antiestrogen therapy …
Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase II neoadjuvant study in HR+/HER2 …
SA Hurvitz, M Martin, MF Press, D Chan… - Clinical Cancer …, 2020 - aacrjournals.org
Purpose: neoMONARCH assessed the biological effects of abemaciclib in combination with
anastrozole in the neoadjuvant setting. Patients and Methods: Postmenopausal women with …
anastrozole in the neoadjuvant setting. Patients and Methods: Postmenopausal women with …
[HTML][HTML] Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer
Background Invasive lobular breast cancer (ILC) is the second most common type of breast
cancer after invasive breast cancer of no special type (NST), representing up to 15% of all …
cancer after invasive breast cancer of no special type (NST), representing up to 15% of all …
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN) …
Background In hormone receptor-positive, HER2-negative early stage breast cancer, cyclin-
dependent kinases 4 and 6 (CDK4/6) inhibition in combination with endocrine therapy could …
dependent kinases 4 and 6 (CDK4/6) inhibition in combination with endocrine therapy could …
[HTML][HTML] Targeting cell cycle in breast cancer: CDK4/6 inhibitors
Deregulation of cell cycle, via cyclin D/CDK/pRb pathway, is frequently observed in breast
cancer lending support to the development of drugs targeting the cell cycle control …
cancer lending support to the development of drugs targeting the cell cycle control …